SHUTTLE PHARMACTCLS HLDGS INC Stock Price, News & Analysis

Shuttle Pharmaceuticals (Nasdaq: SHPH) announced a non-binding letter of intent dated Oct 9, 2025 to acquire AI developer Molecule.ai for a $10 million purchase price payable at closing subject to milestones.

Molecule.ai provides an AI drug-discovery platform using LLMs with modules for molecule property prediction, drug-target interaction modeling, and an initial Agentic AI mode to automate multi-step discovery workflows. Shuttle will acquire all rights and assume liabilities; Molecule.ai will extend the platform and assist hiring. Consideration will be a mix of cash and Shuttle common shares tied to milestone completion.

Shuttle Pharmaceuticals (Nasdaq: SHPH), a specialty pharmaceutical company focused on improving radiation therapy outcomes, provided a Q2 2025 corporate update highlighting significant progress in its clinical trials. The company's Phase 2 trial of Ropidoxuridine for glioblastoma treatment has reached 63% enrollment, with 72% of enrolled patients completing all seven cycles and reporting good tolerability.

Key financial developments include securing $4.25 million through a private placement, ending Q2 with $4.8 million in cash. The company completed a reverse stock split for Nasdaq compliance and strengthened its leadership by appointing George Scorsis as Board Chairman and Christopher Cooper to the Board. The Phase 2 trial completion is expected in late 2025, with data readouts anticipated in 2026.

Shuttle Pharmaceuticals (Nasdaq: SHPH), a specialty pharmaceutical company focused on improving cancer radiation therapy outcomes, has completed a $4.25 million private placement with an accredited investor. The company issued 1,180,877 shares of common stock (or pre-funded warrants) at $3.60 per share, priced at-the-market under Nasdaq rules.

The net proceeds will be used for potential acquisitions, marketing, and general corporate purposes. WestPark Capital served as the exclusive placement agent. The company has agreed to file registration statements with the SEC for the resale of the shares and warrant shares.

Shuttle Pharmaceuticals (SHPH) has secured a $4.25 million private placement through a securities purchase agreement with an accredited investor. The company will issue 1,180,877 shares of common stock or pre-funded warrants at $3.60 per share, priced at-the-market under Nasdaq rules. The proceeds will support potential acquisitions, marketing, and general corporate purposes. WestPark Capital serves as the exclusive placement agent, with the offering expected to close around June 23, 2025. The securities are offered only to accredited investors and are not registered under the Securities Act of 1933. Shuttle Pharma has agreed to file registration statements for the resale of the shares and warrant-eligible shares.

Shuttle Pharmaceuticals (NASDAQ: SHPH) has announced a 1-for-25 reverse stock split effective June 16, 2025, at 12:01 a.m. ET. The company's common stock will continue trading under the symbol SHPH on the Nasdaq Capital Market with a new CUSIP number 825693401. The split will reduce outstanding shares from 26,210,037 to approximately 1,048,401 and will apply to RSU grants and warrants. Fractional shares will be rounded up to the next whole number. This strategic move aims to maintain Nasdaq listing compliance and strengthen the company's capital structure. Shuttle Pharma, a specialty pharmaceutical company, focuses on developing radiation sensitizers to improve outcomes for cancer patients undergoing radiation therapy.

Shuttle Pharmaceuticals (SHPH) has announced a proposed 25-for-1 reverse stock split to maintain Nasdaq listing compliance. The split will reduce outstanding shares from 26.2 million to approximately 1.05 million shares, pending Nasdaq approval. The action will affect all common stock, including RSU grants and warrants, with fractional shares being rounded up. Shuttle Pharma, a specialty pharmaceutical company, focuses on developing radiation sensitizers to enhance radiation therapy outcomes for cancer patients while minimizing side effects. The reverse split is positioned as a strategic move to strengthen the company's long-term capital structure while ensuring continued Nasdaq listing compliance.

Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) has appointed George Scorsis as Chairman of the Board of Directors, effective June 4, 2025. Scorsis, who has served as a director since February 2025, brings over 25 years of experience leading companies in regulated industries. His extensive leadership background includes roles as President at Mettrum Health Corp, CEO of Liberty Health Sciences, and Chairman positions at SOL Global Investments, Entourage Health Corp, and AWAKN Life Sciences. Shuttle Pharma is focused on developing radiation sensitizers to enhance cancer treatment outcomes, specifically targeting improved cure rates, patient survival, and quality of life for patients undergoing radiation therapy.

Shuttle Pharmaceuticals (NASDAQ: SHPH) provided a corporate update on its cancer treatment developments. The company reported significant progress in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, achieving nearly 50% enrollment with 84% of patients completing all seven cycles. The drug is being well-tolerated with toxicity no greater than 2 on a 1-5 scale.

The company has expanded its diagnostic capabilities through a research agreement with UCSF for developing PSMA-targeted ligands for cancer theranostics. Shuttle Pharma also filed a provisional patent for "PSMA-Targeted PARP Inhibitor Conjugates." The company strengthened its board with three new directors and reported $4.5 million in cash as of March 31, 2025. Notable management changes include the resignation of CSO Dr. Anatoly Dritschilo and upcoming retirement of VP Regulatory Michael Vander Hoek.

Shuttle Pharmaceuticals (NASDAQ: SHPH) has reached nearly 50% enrollment in the initial randomized portion of its Phase 2 clinical trial for Ropidoxuridine, targeting glioblastoma treatment. The trial has shown promising initial results with the drug being well-tolerated and 84% of enrolled patients completing all seven cycles. The study involves 40 patients randomized into two dose levels (1,200 mg/day and 960 mg/day), with plans to add 14 more patients at the optimal dose. Ropidoxuridine, which has received FDA Orphan Drug Designation, is being developed as a radiation sensitizer for brain tumors. The trial is being conducted across six major medical centers, with final enrollment expected later this year and data readout in 2026. The company targets a significant market opportunity, with an estimated 400,000 US patients receiving radiation therapy for curative purposes annually, expected to grow by 22% over five years.